Abstract
Cardinal Health will report fiscal third-quarter 2026 results on April 30, 2026, Pre-Market; the Street expects revenue growth to continue alongside double-digit adjusted EPS expansion, with investors focused on specialty distribution momentum, margin trajectory, and updates on precision health initiatives.Market Forecast
Consensus for the current quarter points to revenue of 61.67 billion US dollars, up 11.42% year over year, EBIT of approximately 0.94 billion US dollars with 25.58% year-over-year growth, and adjusted EPS of about 2.79 US dollars, up 28.79% year over year. Margin forecasts are not formally indicated; investors will benchmark results against the prior quarter’s gross profit margin of 3.65% and net profit margin of 0.71% when assessing profit quality and leverage.The main business remains the Pharmaceutical and Specialty Solutions segment, which generated 60.67 billion US dollars last quarter; near-term performance should mirror specialty-drug volume trends and purchasing dynamics indicated in recent updates. The segment with the most near-term optionality is the precision health–adjacent portfolio housed in “Other,” which posted 1.72 billion US dollars last quarter and stands to benefit from the announced expansion of Actinium-225 production capacity; management has also highlighted that specialty-related revenues are pacing toward more than 50.00 billion US dollars in fiscal 2026 on a multi-year double-digit growth trajectory.
Last Quarter Review
In fiscal Q2 2026, Cardinal Health delivered 65.63 billion US dollars in revenue, a gross profit margin of 3.65%, GAAP net profit attributable to shareholders of 467.00 million US dollars with a net profit margin of 0.71%, and adjusted EPS of 2.63 US dollars; revenue rose 18.75% year over year and adjusted EPS increased 36.27% year over year. A key financial highlight was EBIT of 0.88 billion US dollars, up 38.11% year over year, demonstrating stronger operating leverage than top-line growth.Main business highlights showed Pharmaceutical and Specialty Solutions at 60.67 billion US dollars, Global Medical Products and Distribution at 3.26 billion US dollars, and Other at 1.72 billion US dollars, with the core pharmacy and specialty channel accounting for the vast majority of quarterly sales and driving the company’s 18.75% year-over-year revenue expansion.
Current Quarter Outlook
Main business: Pharmaceutical and Specialty Solutions
This segment is expected to set the tone for the quarter’s results given its 60.67 billion US dollars contribution last period and the forecasted company-level revenue of 61.67 billion US dollars. The key watch items are specialty-brand volume throughput, the cadence of new therapy launches, and purchasing dynamics with manufacturers, which can influence quarterly revenue recognition and rebate timing. With consensus modeling 11.42% year-over-year revenue growth and 25.58% EBIT growth at the consolidated level, the setup implies continued operating leverage from mix and scale within the core distribution engine, even if gross margin remains low in basis due to the nature of the channel.Management’s previously stated multi-year ambition for specialty underscores the durability of demand in complex therapies that move through the specialty channel. Given the thin net margins typical for this business (0.71% last quarter), incremental improvements in procurement terms, distribution fees, and service-level efficiencies can have an outsized effect on EBIT and EPS. Investors will also monitor working capital discipline and inventory turns, as these influence free cash conversion and can either amplify or dampen the earnings flow-through of volume-led revenue growth.
Most promising business: Precision health and radiopharmaceuticals within “Other”
Cardinal Health disclosed an expansion of Actinium-225 production capabilities at its Center for Theranostics Advancement, directly addressing a bottleneck in supply for investigational targeted alpha therapies. While this portfolio sits within “Other,” which delivered 1.72 billion US dollars in the most recent quarter, the incremental capacity has strategic significance: it positions the company to capture downstream manufacturing and distribution activity as clinical development of radiopharmaceuticals advances. Over time, that can enrich margin mix given the higher service intensity and technical barriers associated with radiopharmaceutical logistics and production.In the near term, investors will not expect a step-change in revenue from this capacity alone; the commercial timeline of novel therapies remains the gating factor. However, evidence of increased isotope availability supports more clinical activity and broadens the potential pipeline of future commercial supply agreements. The update also aligns with management’s posture that specialty and adjacent services are growing at double-digit rates over a multi-year period, creating an embedded growth vector that is less correlated with traditional generic-price deflation cycles.
Key stock-price swing factors this quarter
- Margin trajectory versus tough comparisons: With a 3.65% gross margin and 0.71% net margin last quarter, modest shifts in mix and fee economics can move EPS materially. The Street’s 28.79% year-over-year adjusted EPS growth forecast for Q3 implies improved operating efficiency or a richer mix; any under- or outperformance here should drive the post-earnings reaction more than revenue variance given the predictability of top-line pass-through dynamics. - Specialty revenue cadence and qualitative color: Management’s commentary around specialty volumes and any updates tied to the previously communicated path to more than 50.00 billion US dollars of specialty revenue in fiscal 2026 will be parsed for sustainability and sequencing into fiscal Q4. Commentary on therapy class momentum and manufacturer relationships can recalibrate medium-term models. - Precision health milestones and capital allocation: Incremental details on Actinium-225 ramp timing, new customer engagements, or expanded capabilities could extend the multiple as investors ascribe higher long-term mix. Separately, cash deployment—whether toward working capital needs, dividends, or targeted investments—can influence perceptions of balance between growth, resilience, and shareholder returns.Analyst Opinions
Recent sell-side commentary since January 1, 2026, skews decisively bullish, with multiple Buy/Outperform reiterations and target raises outweighing a single Neutral stance; the majority view anticipates continued top-line growth and further operating leverage into fiscal Q3. Several well-followed firms have expressed confidence that specialty-led execution and incremental margin improvement can sustain double-digit EPS growth in the near term, consistent with the 28.79% year-over-year adjusted EPS increase implied by consensus.- Barclays has maintained an Overweight rating and lifted its price target into the mid-250s, emphasizing that year-to-date execution supports above-market growth and that operating leverage should improve as mix skews toward specialty and services. The firm’s thesis aligns with the forecasted 25.58% year-over-year growth in EBIT this quarter, implying confidence in margin capture without requiring an outsized step-up in gross margin. - Evercore ISI continues to rate the shares Outperform, noting that the company’s upgraded fiscal 2026 outlook earlier this year reflected momentum across core distribution and specialty, with room for additional upside from services that scale with therapy complexity. Their stance suggests that even as gross margins remain structurally low, the company can expand operating profit through scale efficiencies and mix, consistent with the last quarter’s 38.11% year-over-year EBIT growth and the higher EPS run-rate. - Baird has reiterated its Outperform view and nudged its target higher, citing favorable multi-quarter visibility in specialty volumes and evidence of disciplined cost management. Analysts point to the gap between top-line growth and EPS growth as a sign that incremental operating leverage is becoming more durable, an important signal ahead of what is typically a seasonally mixed spring quarter. - Leerink Partners has sustained an Outperform rating while increasing its target toward the high-200s, framing precision health and radiopharmaceuticals as a credible medium-term mix enhancer. The firm views the expansion of Actinium-225 capacity as strategically valuable in deepening relationships with biopharma partners and enabling supply reliability for emerging radioligand therapies. - Argus has reiterated Buy with a higher target in the high-240s, highlighting that double-digit revenue growth paired with disciplined execution can deliver EPS compounding above revenue growth for the foreseeable quarters, which is consistent with consensus for 11.42% revenue growth and 28.79% EPS growth in the current period. - Wells Fargo’s maintained Buy underscores that the stock’s performance remains tethered to execution in specialty and stability in fee economics. The team expects another quarter of solid throughput in the core business and sees optional upside from services attached to complex therapies. - JPMorgan’s Neutral serves as a minority view, focusing on valuation following a strong run and the need for incremental catalysts to re-rate further. Even within this stance, the firm acknowledges steady fundamentals and a supportive setup into the print.
Synthesis of the majority view: Analysts broadly expect a “beat-and-raise” or at least an in-line revenue outcome with better-than-feared margins that keep the EPS trajectory ahead of revenue growth. The strongest part of the bull case centers on the durability of specialty revenue momentum and the compounding effect of scale efficiencies on operating profit, evidenced by the last quarter’s 38.11% year-over-year EBIT growth and the Street’s 25.58% EBIT growth forecast for Q3. Incremental enthusiasm is attached to precision health and radiopharmaceutical capabilities, where the Actinium-225 capacity expansion offers a tangible proof point of investment in higher-value services that can improve mix over time.
For this quarter, bulls will focus on three validation points: delivering revenue near 61.67 billion US dollars with a steady gross margin base relative to last quarter’s 3.65%; translating that into EBIT around 0.94 billion US dollars; and converting operating performance into adjusted EPS near 2.79 US dollars. Clear commentary on specialty revenue pacing and any color on the pipeline for theranostics support will be viewed as incremental positives, while even modest improvement in net margin from the prior 0.71% would reinforce the operating leverage narrative. In short, the consensus bullish view is that Cardinal Health enters the quarter with constructive momentum, and that specialty-led execution, tight expense control, and expanding precision-health capabilities can sustain above-revenue EPS growth into fiscal Q4 and beyond.
Comments